Argos Therapeutics Inc. (NASDAQ:ARGS)’s share price fell 10.7% during mid-day trading on Tuesday . The company traded as low as $4.62 and last traded at $4.66, with a volume of 337,870 shares traded. The stock had previously closed at $5.22.

A number of brokerages have recently issued reports on ARGS. FBR & Co reissued a “buy” rating on shares of Argos Therapeutics in a research note on Saturday, May 14th. Zacks Investment Research raised Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a research note on Monday, August 15th. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Argos Therapeutics in a research note on Friday, June 17th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $11.00 price target on shares of Argos Therapeutics in a report on Monday, June 20th. Eight research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $11.50.

The company’s 50 day moving average price is $5.22 and its 200 day moving average price is $5.92. The company’s market cap is $205.98 million.

Argos Therapeutics (NASDAQ:ARGS) last issued its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.05. On average, equities analysts forecast that Argos Therapeutics Inc. will post ($1.49) earnings per share for the current year.

In related news, major shareholder International S. Pharmstandard bought 75,474 shares of the firm’s stock in a transaction on Monday, August 22nd. The stock was bought at an average cost of $4.24 per share, for a total transaction of $320,009.76. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder International S. Pharmstandard bought 67,371 shares of the firm’s stock in a transaction on Wednesday, August 24th. The stock was bought at an average price of $4.52 per share, with a total value of $304,516.92. The disclosure for this purchase can be found here.

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.